Medicare price negotiations reduce drug costs by 15% by Q4 2026

Trump’s policy push includes mandatory Medicare price negotiations for top-selling drugs. Historically, such negotiations have led to 10-20% cost reductions. Market pressure from pharma lobby resistance could limit but not fully block these cuts.

Implied probability (Yes)

72%